Should Hepatitis C Virus Antibody Be Used for Screening Purposes?

Basit Öğe Kaydı
dc.authorwosidŞafak, Birol/A-3698-2017
dc.authorwosidŞafak, Birol/AAD-4429-2021
dc.authorwosidErtan, Asli/AAE-6201-2021
dc.contributor.authorŞafak, Birol
dc.contributor.authorTombak, Özge
dc.contributor.authorEren Topkaya, Aynur
dc.date.accessioned2022-05-11T14:42:11Z
dc.date.available2022-05-11T14:42:11Z
dc.date.issued2018
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractObjectives: In this study, hepatitis C virus (HCV) RNA results were retrospectively investigated in patients with reactive HCV antibodies. Materials and Methods: HCV antibody test was performed ELISA method. Enzyme linked fluorescence assay was used as a different method. The quantitative HCV RNA test was carried out by AmpliPrep/COBAS TaqMan HCV test. Results: HCV antibody reactivity was detected in 358 of 28081 samples, 255 samples collected from 358 anti-HCV positive-patients and were tested for HCV RNA were included in the study. The detected HCV RNA positivity rate was 5.8% in patients who had low titer reactive HCV antibody and 76.3% in patients, who had high titer reactive HCV antibody. Nine of 23980 samples, which were screened for preoperative preparation, had reactive HCV RNA. One hundred thirty seven of 4101 samples, which were obtained for diagnostic purposes in the gastroenterology and infectious diseases clinics, were HCV RNA positive. Conclusion: Positive results should be confirmed with HCV RNA testing; if possible, testing for HCV antibodies with other methods, before HCV RNA testing, will decrease the number of tests using molecular methods; and screening for HCV antibodies is not cost-effective especially in populations with a low prevalence of HCV antibody positivity.
dc.identifier.doi10.4274/vhd.0018
dc.identifier.endpage20
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue1en_US
dc.identifier.startpage18
dc.identifier.urihttps://doi.org/10.4274/vhd.0018
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9266
dc.identifier.volume24
dc.identifier.wosWOS:000433060600005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthorŞafak, Birol
dc.institutionauthorTombak, Özge
dc.institutionauthorEren Topkaya, Aynur
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatitis C virus antibody
dc.subjectscreening
dc.subjectcost effectiveness
dc.subjectViral-Hepatitis
dc.subjectHcv Infection
dc.subjectDiagnosis
dc.titleShould Hepatitis C Virus Antibody Be Used for Screening Purposes?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9266.pdf
Boyut:
101.42 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu